What Is Adderall 7.5 mg?

Adderall 7.5 mg is a low-to-mid strength of the immediate-release (IR) tablet formulation of Adderall. It is a central nervous system (CNS) stimulant prescription medicine classified as a Schedule II controlled substance in the United States due to its high potential for abuse and dependence.

The 7.5 mg strength is commonly used as a titration step for patients who need slightly more than the 5 mg starting dose but do not yet require 10 mg. It allows prescribers to fine-tune treatment in smaller increments before committing to a higher standard strength.

What Adderall 7.5 mg Is Prescribed For

Adderall 7.5 mg is FDA-approved for two conditions:

• Attention-Deficit/Hyperactivity Disorder (ADHD): In children ages 3 to 17 years. It may help increase attention and decrease impulsiveness and hyperactivity.
• Narcolepsy: In people ages 6 years and older.

Adderall is intended as part of a total treatment program for ADHD that may include psychological, educational, and social measures. Drug treatment may not be appropriate for all children with ADHD.

Active Ingredients

The active ingredients in Adderall 7.5 mg are four amphetamine salts:

• Dextroamphetamine saccharate
• Amphetamine aspartate
• Dextroamphetamine sulfate
• Amphetamine sulfate

Each 7.5 mg tablet contains 2.5 mg of dextroamphetamine saccharate, 2.34 mg of amphetamine aspartate equivalent to 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP (0.3 mg of total amphetamine base equivalence).

The 7.5 mg tablet is described as an oval, convex, blue tablet with “7.5” embossed on one side with a partial bisect, and “AD” embossed on the other side with a full and partial bisect. Another manufacturer description lists the 7.5 mg tablet as round, blue, and scored with “b 775/7½” imprint.

Immediate-Release vs. Extended-Release

Adderall 7.5 mg is an immediate-release (IR) tablet. It should not be confused with Adderall XR (extended-release), which is a different formulation with different dosing.

Feature Immediate-Release (IR) Tablets Extended-Release (XR) Capsules Available strengths 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg Onset Usually within 30–60 minutes Delayed initial release Duration Approximately 4–6 hours Approximately 10–12 hours Dosing frequency Often multiple times daily Once daily, typically in the morning Minimum age (ADHD) 3 years 6 years

Note: Based on bioequivalence data, patients taking divided doses of immediate-release Adderall (for example, twice a day) may be switched to Adderall XR at the same total daily dose taken once daily.

Important Safety Information (Boxed Warning)

Abuse, Misuse, and Addiction: Adderall 7.5 mg has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants can result in overdose and death. This risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment and will monitor during treatment.

Adderall 7.5 mg may lead to physical dependence after prolonged use, even if taken as directed.

Do not give Adderall to anyone else. Selling or giving away this medication is against the law and may harm others.

Common Side Effects

Pediatric patients ages 6 to 12: Loss of appetite, insomnia, abdominal pain, emotional lability, vomiting, nervousness, nausea, and fever.

Pediatric patients ages 13 to 17: Loss of appetite, insomnia, abdominal pain, weight loss, and nervousness.

Adults: Dry mouth, loss of appetite, insomnia, headache, weight loss, nausea, anxiety, agitation, dizziness, tachycardia, diarrhea, asthenia, and urinary tract infections.

Important Warnings

Cardiovascular Risks: Sudden death has been reported in patients with structural cardiac abnormalities or other serious heart disease who were treated with CNS stimulants at recommended doses. Adderall 7.5 mg generally should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or coronary artery disease. Adderall causes modest increases in average blood pressure (about 2 to 4 mmHg) and heart rate (about 3 to 6 bpm).

Psychiatric Risks: Stimulants may cause new or worsening mental problems, including psychosis, mania, or bipolar illness. Treatment-emergent psychotic or manic symptoms (such as hallucinations, delusional thinking, or mania) can occur in patients without prior history of psychotic illness. Aggressive behavior or hostility has also been reported.

Long-Term Growth Suppression: CNS stimulants have been associated with weight loss and a slowing of growth rate in children. Careful follow-up of children ages 7 to 10 suggests consistently medicated children may have a temporary slowing in growth rate (on average, about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years). Height and weight should be monitored during treatment.

Peripheral Vasculopathy (Raynaud’s Phenomenon): Stimulants are associated with circulation problems in fingers and toes. Signs include fingers or toes feeling numb, cool, or painful, or changing color from pale to blue to red.

Serotonin Syndrome: A potentially life-threatening reaction that may occur when Adderall 7.5 mg is taken with other serotonergic drugs. Symptoms include agitation, hallucinations, fast heartbeat, flushing, seizures, loss of coordination, confusion, dizziness, changes in blood pressure, sweating or fever, nausea, vomiting, diarrhea, muscle stiffness, and high body temperature. Stop taking Adderall and seek emergency care immediately if these occur.

Seizures: Stimulants may lower the convulsive threshold. Adderall 7.5 mg should be discontinued if seizures occur.

New or Worsening Tics: Adderall 7.5 mg may cause or worsen motor and verbal tics, or worsen Tourette’s syndrome.

Drug Interactions

MAOIs (Monoamine Oxidase Inhibitors): Taking Adderall 7.5 mg with MAOIs, or within 14 days of stopping an MAOI, can cause a hypertensive crisis with potentially fatal outcomes. This combination is contraindicated.

Serotonergic Drugs: Increased risk of serotonin syndrome. Examples include SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort.

CYP2D6 Inhibitors: May increase amphetamine exposure and risk of serotonin syndrome. Examples include paroxetine, fluoxetine, quinidine, and ritonavir.

Alkalinizing Agents (e.g., antacids, sodium bicarbonate): Increase blood levels and potentiate the effects of amphetamine. Co-administration with Adderall 7.5 mg should be avoided.

Acidifying Agents (e.g., ascorbic acid, fruit juices): Lower blood levels and reduce efficacy of amphetamines.

Who Should Not Take Adderall 7.5 mg

Adderall 7.5 mg is contraindicated in patients with:

• Known hypersensitivity or allergic reaction to amphetamine products
• A history of drug abuse
• Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension
• Hyperthyroidism
• Glaucoma
• Agitated states
• Current or recent (within 14 days) use of MAOIs

How Prescriptions Work

As a Schedule II controlled substance, Adderall 7.5 mg prescriptions are subject to strict federal and state regulations:

• No refills allowed: Federal law prohibits refills on Schedule II prescriptions. A new prescription is required each time.
• Limited quantity: Many jurisdictions limit the quantity that can be prescribed at once (often a 30-day supply).
• Regular follow-up: Patients may need regular follow-up visits before receiving a new prescription.
• Lowest effective dose: Prescribers should individualize dosage and use the lowest effective dose.
• Safe storage: Store Adderall 7.5 mg at room temperature (20° to 25°C / 68° to 77°F), protect from light, and keep in a safe place such as a locked cabinet.

Frequently Asked Questions

Is Adderall 7.5 mg safe for long-term use?
The effectiveness of Adderall 7.5 mg for long-term use has not been systematically evaluated in controlled trials. Physicians should periodically re-evaluate the long-term usefulness for each patient.

Does Adderall 7.5 mg affect sleep?
Insomnia is a common side effect. Taking the medication earlier in the day can help minimize sleep difficulties. Afternoon doses should be avoided because of the potential for insomnia.

Can I stop taking Adderall 7.5 mg suddenly?
Abrupt discontinuation after prolonged use can lead to withdrawal symptoms. This should be managed under medical supervision.

What does “7.5 mg” mean in Adderall 7.5 mg?
The 7.5 mg refers to the total amount of the four amphetamine salts combined.

Is Adderall 7.5 mg the same as Adderall XR 7.5 mg?
No. Adderall 7.5 mg is an immediate-release tablet, while Adderall XR is an extended-release capsule. Adderall XR is not available in a 7.5 mg strength.

How does Adderall 7.5 mg compare to Adderall 5 mg?
Adderall 7.5 mg is one titration step higher than 5 mg. It is typically prescribed when a patient needs slightly more symptom control but does not yet require 10 mg. Both are immediate-release tablets with similar onset and duration.

Can Adderall 7.5 mg be split?
The 7.5 mg tablet has a partial bisect on one side. However, patients should only split tablets if instructed by their prescriber, as accurate dosing cannot always be guaranteed.

Conclusion

Adderall 7.5 mg is a low-to-mid strength immediate-release stimulant approved for ADHD and narcolepsy. As a Schedule II controlled substance, it carries a boxed warning for abuse, misuse, and addiction, and requires strict prescribing controls. Common side effects include appetite loss, insomnia, and nervousness. Serious risks include cardiovascular events, psychiatric symptoms, growth suppression in children, and serotonin syndrome when combined with serotonergic drugs. Patients should use the lowest effective dose, monitor height and weight (in children), store the medication securely, and never share it with others. Any changes to treatment should be managed under medical supervision.